Bernard M. Uitdehaag

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Sex-dependent bioactive lipid mediator profiles in multiple sclerosis.

Sex-dependent bioactive lipid mediator profiles in multiple sclerosis.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: March 18, 2026

Understanding the complex network of objectively assessed cognition and self-reported psychological symptoms in people with multiple sclerosis.

Understanding the complex network of objectively assessed cognition and self-reported psychological symptoms in people with multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 09, 2024

Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.

Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 04, 2024

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 18, 2024

Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.

Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 09, 2024

Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.

Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 14, 2024

Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.

Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 29, 2023

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 02, 2023

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: June 29, 2023

Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.

Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 25, 2023

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 05, 2022

Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.

Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 24, 2022

Showing 1-12 of 56

Last Updated: 09/26/2026